Luna Bioscience, a spin-out from the Vinetz laboratory at Yale, translates microbial genomics to vaccines, diagnostics, and therapeutics for emerging, globally-important infectious diseases. Candidates are identified using a platform technology that exploits genomics, which yields diverse therapeutic targets. We are addressing huge unmet needs starting with blockbuster leptospirosis vaccine products in the USA and global animal leptospirosis vaccine markets, which will enable company profitability through sustained funding for humans products via the animal health markets.